Update of the effect of antihyperglycemic agents on renal function in type 2 diabetes mellitus
DOI:
https://doi.org/10.51481/amc.v60i2.997Keywords:
Diabetes mellitus type 2, Diabetic nephropathy, IDPP-4, ISGLT2, Metformin, thiazolidinediones, sulphonylureas, insulin, glomerular filtration rate, GLP-1 analogsAbstract
Type 2 diabetes mellitus is one of the metabolic diseases that affects different organs, one of which is the kidney. One of the main microvascular complications is diabetic nephropathy, being the main cause of chronic renal failure worldwide. Hence the importance of recommendations on the use or non-use of antihyperglycemic drugs based on their beneficial effects on kidney function, expressed by the estimated glomerular filtration rate and the albumin / creatinine ratio in patients with type 2 diabetes mellitus and kidney disease. Recent studies have shown antihyperglycemic agents with beneficial impact in cardiovascular and renal endpoints. In the present article we will review the actions and effects of different groups of drugs such as metformin, inhibitors of dipeptidyl peptidase 4, GLP-1 agonists, thiazolidinediones, sulfonylureas, SGLT-2 inhibitors and insulins in renal function in relation to the doses of each drug, both the use of established doses, reduction of the dose or nonuse of the drug based on the worsening of the estimated glomerular filtration rate and albumin/ creatinine ratio. Prestigious journal articles were used with less than 5 years since its publication, however articles that exceed this time were used as they provided important data in the review article.
Downloads
References
Sharma D, Bhattacharya P, Kalia K, Tiwari V et al. Diabetic Nephropathy: New insights into established therapeutic paradigms and novel molecular targets. Diabetes Res Clin Pract. 2017; 128:91-108.
Duran M., Rubio A. Diabetic nephropathy and inflammation. World J Diabetes. 2014 June 15; 5: 393-398.
Tonneijck L, Muskiet M, Smits M, Van Bommel E, Heerspink H, Raalte D, Joles J. et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol.2017; 28: 1023-1039.
Levey A, Stevens L. Estimating GFR Using the CKD Epidemiology Collaboration
(CKDEPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions. Am J Kidney Dis. 2010; 55: 622-627.
Wood A, Churilov L, Perera N, Thomas D, Poon A, MacIsaac R, et al. Estimating glomerular filtration rate: Performance of the CKD-EPI equation over time in patients with type 2 diabetes. Journal of Diabetes and its Complications, vol. 30, no. 1, pp. 49-54.
Cartet-Farnier E, Goutelle-Audibert L, Maire P, De la Gastine B. and Goutelle S. Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients. Fundam Clin Pharmacol. 2017; 31: 110-119.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 Interim Update. Can J Diabetes. 2016; 40: 484-486.
Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:9 574-9.
Holman R, Paul S, Bethel M, Matthews D, Neil H, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:15771589.
Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm. T2D Algorithm, Executive Summary. Endocr Pract. 2017; 23:207-238.
Inzucchi S, Lipska K, Mayo H, Bailey C, McGuire D. Metformin in patients with type 2 diabetes and kidney disease. JAMA. 2014; 312:2668-75.
Cefalu W, Bakris G, Blonde L, Boulton A, Greene E, Hu F, et al. Standards of Medical Care in Diabetes. Diabetes Care. 2017; 40:S4-S5.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis. 2012; 60:850-886.
Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, M. Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 34:535-42.
Davis T, Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes Obes Metab. 2014; 16:891-9.
Scirica B, Deepak L, Bhatt D, Braunwald E, Steg P, Davidson J, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369:1317-1326.
Mosenzon O, Leibowitz G, Bhatt D, Cahn A, Hirshberg B, Wei C, et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2017; 40:69-76.
Ceriello A, Inagaki N. Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. J Diabetes Investig 2017; 8: 19-28.
Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutr Metab Cardiovasc Dis. 2016; 26:361-73.
Engel S, Suryawanshi S, Stevens S, Josse R, Cornel J, Jakuboniene N, on behalf of the TECOS Study Group et al. Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS. N Engl J Med 2015; 373:232-42.
Lukashevich V, Schweizer A, Shao Q, Groop P, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebocontrolled trial. Diabetes Obes Metab. 2011; 13:947-54.
Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen T. The effect of liraglutide on renal function: A randomised clinical trial. Diabetes Obes Metab. 2017; 19:239-247.
Marso S, Daniels G, Brown‑Frandsen K, Kristensen P, Mann J, Nauck M, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375:311-22.
Mann J, Orsted D, Brown‑Frandsen K, Marso S, Poulter N, Rasmussen S, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377:839-48.
Davies M, Bain S, Atkin S, Rossing P, Scott D, Shamkhalova M et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016; 39:222-30.
Marbury T, Flint A, Jacobsen J, Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017. doi: 10.1007/s40262-017-0528-2.
Marso S, Bain S, Consoli A, Eliaschewitz F, Jódar E, for the SUSTAIN-6 Investigators, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375:1834-44.
Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. diabetes care. 2016; 39: S165-71.
Scheen A. Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. Clin Pharmacokinet. 2014; 53:213-225.
Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375:323-34.
Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S, for the EMPAREG OUTCOME Investigators et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-28.
Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni A, et al. Mechanisms Linking Empagliflozin to Cardiovascular and Renal Protection. Int J Cardiol. 2017; 241:450-456.
Inagaki N, Kondo K, Yoshinari T, Ishii M, Sakai M, Kuki H, et al. Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment. Clin Drug Investig. 2014; 34:731-742.
Neal B, Perkovic V, Mahaffey K, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:644-657.
Heerspink H, Desai M, Jardine M, Balis D, Meininger G, Perkovic V, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017; 28:368-375.
Desai M, Yavin Y, Balis D, Sun D, Canovatchel J, Rosenthal N, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2. Diabetes Obes Metab. 2017; 19:897-900.
Filippatos T, Liberopoulos E, Elisaf M. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015, 6:29- 41.
Fioretto P, Stefansson B, Johnsson E, Sjöström C. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016; 59:2036-9.
Kohan D, Fioretto P, Weihua Tang W, List J. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014; 85:962-71.
Ochodnicky P, Mesarosova L, Cernecka H, Klimas J, Krenek P, Goris M, et al. Pioglitazone, PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Eur J Pharmacol. 2014; 730:51-60.
Chang Y, Hwu D, Chang D, Wang An L, Hsun Hsieh C, Jiunn Lee Y, et al. Renal function preservation with pioglitazone or with basal insulin as an addon therapy for patients with type 2 diabetes mellitus. Acta Diabetol. 2017; 54:561-568.
Snyder R, S. Berns J. Use of Insulin and Oral Hypoglycemic Medications in Patients with Diabetes Mellitus and Advanced Kidney Disease. Semin Dial. 2004; 17:365-70.
Neumiller J, Alicic R, Tuttle K. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. J Am Soc Nephrol. 2017; 28:2263-2274.
Downloads
Published
Versions
- 2018-05-03 (2)
- 2018-05-03 (1)
Issue
Section
License
Copyright (c) 2018 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
